Budget Pressures Are Hampering Science Efforts, FDA And NIH Heads Say
This article was originally published in The Pink Sheet Daily
It will "certainly make it very hard to run an agency, when you don't know what your budget is, going forward," FDA Commissioner Margaret Hamburg says.
You may also be interested in...
When Senators ask whether the U.S. is prepared for a nuclear disaster similar to one following the Japanese earthquake, FDA chief touts agency program that could help develop radiation treatments.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.